Clinical trial

Program on Genetic and Dietary Predictors of Drug Response in Rural and AI/AN Populations, Project-3, SA-3, Anti-platelet Response

Name
SITE00000212
Description
This study will investigate differences in platelet aggregation under basal and aspirin-treated conditions in American Indian and Alaska Native people who have extreme levels (low and high) of n-3 polyunsaturated fatty acids (n-3 PUFAs, EPA and DHA) in red blood cell membranes. The study will also determine whether or not platelet aggregation under the different conditions is modified by CYP4A11, CYP4F2, CYP4F11, PEAR1, and ACTN1 gene variation.
Trial arms
Trial start
2016-08-01
Estimated PCD
2023-07-31
Trial end
2023-07-31
Status
Terminated
Phase
Early phase I
Treatment
Aspirin
Low and high n-3 PUFA participants will receive 81-mg aspirin once a day, for 6 days.
Arms:
Low and High n-3 PUFA
Size
126
Primary endpoint
PFA-100 Platelet Aggregation Test
Single 9 am blood sample on day 3 of study
Eligibility criteria
Inclusion Criteria: 1. Participants with no history of significant medical conditions including cardiac, pulmonary, hepatic, gastrointestinal, or renal disease, or HIV. 2. Participants will be males or females, 18 years or older. 3. Participants will be self-identified as: Yup'ik or Cup'ik (YK-Delta), AI/AN (SCF), or a member of the Confederated Salish and Kootenai Tribe (Flathead Reservation). 4. Participants must read and understand English or Yup'ik. 5. Participants must be able to provide informed consent. Exclusion Criteria: 1. Participants with any significant chronic medical condition, including cardiac, pulmonary, hepatic, gastrointestinal, or renal disease, or HIV. 2. Participants less than 18 yrs of age. 3. Participants unable to read and understand English or Yup'ik. 4. Participants unable to provide informed consent. 5. Recent (within 2 weeks) use of aspirin, NSAIDs, antihistamines, or any prescription anticoagulant drug such as warfarin.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'In this study we will recruit individuals who have previously been determined to have low or high RBC n-3 PUFA content and test platelet function at baseline and after 2-day aspirin treatment.', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 126, 'type': 'ACTUAL'}}
Updated at
2023-12-15

1 organization

1 drug

1 indication